Indivior Pharmaceuticals (INDV) Notes Payables (2021 - 2023)

Indivior Pharmaceuticals has reported Notes Payables for 3 years, with the latest figure at $3.0 million in Q4 2023.

• On a quarterly basis, Notes Payables changed 0.0% year-over-year to $3.0 million in Q4 2023; TTM through Dec 2023 was $3.0 million, a 0.0% change from a year earlier, with the FY2023 full-year figure at $3.0 million, changed 0.0% from the prior year.
• Notes Payables was $3.0 million for Q4 2023 at Indivior Pharmaceuticals, roughly flat from $3.0 million in the prior quarter.
• The five-year high for Notes Payables was $3.0 million in Q4 2021, with the low at $3.0 million in Q4 2021.
• Average Notes Payables over 3 years is $3.0 million, with a median of $3.0 million recorded in 2021.
• The largest YoY upside for Notes Payables was 0.0% in 2022 against a maximum downside of 0.0% in 2022.
• Over 3 years, Notes Payables stood at $3.0 million in 2021, then changed by 0.0% to $3.0 million in 2022, then changed by 0.0% to $3.0 million in 2023.
• The last three Notes Payables figures came in at $3.0 million (Q4 2023), $3.0 million (Q4 2022), and $3.0 million (Q4 2021), per Business Quant data.